Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Trial Profile

A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs ASP-6981 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Jul 2018 Status changed from recruiting to completed.
    • 13 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top